Creative Touch Permanent Makeup and Aesthetics

Injectable skin boosters are a category of intradermal preparations whose primary active is hyaluronic acid (HA), designed to restore the structural hydration and mechanical environment of the dermis rather than add visible volume. Their central mechanism – beyond immediate water-binding hydration – is mechanical activation of fibroblast collagen synthesis through the restoration of dermal tension. Injected HA creates physical stretch in the dermal matrix, which fibroblasts detect via mechanoreceptors and translate into TGF-β signalling and procollagen I production; biopsy-confirmed at four weeks and sustained for six to nine months. Profhilo, the most clinically documented preparation in this category, achieves this through NAHYCO thermal stabilisation technology – producing Hybrid Cooperative Complexes at 32mg/ml total HA without chemical cross-linking agents. The skin booster category ranges from pure HA preparations to hybrid formulations combining HA with polynucleotides, amino acids, or peptides, each with distinct mechanisms and evidence bases.

Injectable skin boosters are intradermal preparations designed to restore the dermis’s structural hydration and mechanical environment, stimulating fibroblast activity and improving skin quality through a mechanism that is distinct from both dermal fillers and mesotherapy. Where fillers add localised volume and maintain it through cross-linked gel persistence, skin boosters integrate broadly into the dermal matrix, restore the physical tension that drives fibroblast mechanosensing, and in doing so activate collagen synthesis pathways that persist well beyond the degradation of the HA itself. That distinction – between adding volume and restoring a functional biological environment – is the most important clinical framing for this category.

The Primary Mechanism: Mechanoreception and TGF-β Activation

The mechanism that separates skin boosters from other hydration treatments is not the water-binding capacity of HA but what happens structurally in the tissue once HA is present. Injected HA creates physical volume in the dermal extracellular matrix, restoring the mechanical tension that fibroblasts detect through integrin-linked mechanoreceptors. This mechanical stimulus activates TGF-β signalling within adjacent fibroblasts – the same growth factor pathway that collagen synthesis depends on – driving measurable procollagen I production. Biopsy-confirmed evidence demonstrates new Type I collagen bundles at four weeks post-injection, sustained for six to nine months whilst the structurally integrated HA remains.

This is clinically meaningful for a specific reason. In photoaged skin, direct TGF-β signalling – the route that iPRF and growth factor treatments depend on – is specifically impaired by chronic UV-driven ROS and AP-1 pathway activation. The mechanical activation of TGF-β through fibroblast mechanoreception bypasses that impaired signalling environment. The signal is coming from the physical architecture of the dermis, not from an exogenous growth factor attempting to bind a compromised receptor pathway. ^[1]

HA also engages CD44 and CD168 receptors on fibroblasts directly, stimulating endogenous HA synthesis and ECM maintenance independently of the mechanical route. As the injected HA degrades, released fragments of varying molecular weights interact with these receptors, providing a continued signalling stimulus during the degradation period rather than simply disappearing.

Profhilo: NAHYCO Technology and the HyCoCo Difference

Profhilo is the most extensively documented skin booster preparation in clinical use and is worth understanding at the molecular level, because its formulation is genuinely distinct from standard cross-linked HA products.

Standard cross-linked skin boosters use BDDE (1,4-butanediol diglycidyl ether) or similar chemical agents to form covalent bonds between HA chains, creating a gel that resists enzymatic degradation and maintains structure. Profhilo uses thermal processing instead. High Molecular Weight HA (H-HA, 1100–1400 kDa, 32mg) and Low Molecular Weight HA (L-HA, 80–100 kDa, 32mg) are heated to break their existing hydrogen bonds, then cooled so that new hydrogen bonds form between H-HA and L-HA chains. The result – Hybrid Cooperative Complexes (HyCoCos) – is a stabilised preparation at 32mg/ml total HA concentration without any chemical cross-linking agent. This matters clinically because the absence of BDDE improves biocompatibility, and because HyCoCo thermal stability confers enzymatic resistance comparable to weakly cross-linked gels, producing the persistence needed for sustained fibroblast activation without the rigidity that would prevent the natural tissue spreading characteristic of the preparation.

The spreading behaviour of Profhilo – each bolus depot diffusing across approximately 10cm² from the injection point – is a direct consequence of its low viscosity (tan delta >1). Five bilateral injection points (the BAP technique: 10 total injections) treat the full facial dermis with minimal needle trauma. The preparation stimulates production of collagen Types I, III, IV, and VII alongside elastin and endogenous HA, making it one of the few injectable preparations with documented effects across all four clinically relevant collagen types.

The Product Landscape

The skin booster category is not homogeneous, and the distinctions between preparations are mechanistically meaningful.

Profhilo Structura warrants specific mention because it represents a distinct clinical indication rather than a more concentrated version of the same treatment. At 45mg/ml delivered into the lateral cheek fat compartment via cannula, it targets subcutaneous adipose tissue regeneration – addressing the volume loss from fat pad atrophy that underlies midface sinking and sagging. This is a fundamentally different depth of treatment and different biological target from classic Profhilo, which works in the dermis. They are not interchangeable and serve different presentations.

A note on hybrid formulations: Derma-Bio (Derma 2.0) combines HA (40mg/ml, dual molecular weight) with polynucleotides (22mg/ml PDRN), 11 amino acids, B vitamins, and biomimetic peptides in a single preparation delivered via mesotherapy or microneedling. Preparations of this type bridge the skin booster and mesotherapy categories – bringing genuine PN regenerative mechanisms and amino acid substrate provision alongside the HA hydration signal. The trade-off is that compound formulations make it difficult to attribute observed results to specific components, and brand-level clinical trials are absent; the evidence relies on individual ingredient science rather than the preparation itself.

Clinical Pearl TKN HA 3’s 3000 kDa molecular weight closely matches physiological dermal HA (2500–3500 kDa), which may be significant for CD44 receptor engagement specificity. Its HYAsep manufacturing process avoids autoclaving – standard autoclaving degrades HA molecular weight by approximately 50% – preserving the structural profile that makes high-MW HA clinically relevant. However, no independent peer-reviewed trials exist for this specific product; evidence is manufacturer-derived.

Evidence Base

Profhilo carries the strongest evidence base in this category. A three-year post-marketing safety assessment covering over 40,000 patients confirmed excellent biocompatibility and a minimal adverse event profile. Multiple clinical studies demonstrated that 100% of patients showed improved tissue quality following a two-treatment initial course. A clinical trial of Profhilo Structura (n=50) showed significant improvement in facial volume and laxity scores with 98.7% patient satisfaction. Comparative data against Volite demonstrated superior hydration and collagen stimulation outcomes for Profhilo.

For the mechanoreception mechanism, biopsy and advanced microscopy evidence from a 2024 in vivo human study of CL-HA injection in photoaged skin over-60 participants confirms fibroblast elongation detectable at one week, thick procollagen I-positive collagen bundles by four weeks, and collagen accumulation sustained at twelve months whilst CL-HA remained present. ^[2]

Brand-specific evidence for TKN HA 3 and Kiara is absent from the independent peer-reviewed literature; both rely on general HA skin booster science. Product selection within the HA booster category should therefore prioritise formulation rationale and the established Profhilo evidence where the clinical goal is collagen stimulation, reserving less-evidenced preparations for contexts where their specific formulation characteristics (molecular weight profile, hybrid actives, device compatibility) offer a distinct advantage.

Skin Boosters vs Dermal Fillers

The distinction is worth stating clearly because clients frequently conflate them. Dermal fillers use highly cross-linked HA with sufficient viscosity to stay localised and provide structural volume – adding shape to lips, cheeks, or tear troughs. Skin boosters, even Profhilo at the highest available concentration, are designed to spread and integrate rather than maintain shape; they improve quality, hydration, and collagen density but do not change facial contour. A client asking to address significant cheek volume loss, deep nasolabial folds, or lip shape needs a filler discussion, not a skin booster discussion. These are genuinely different tools, and treating the distinction casually produces both disappointing outcomes and unmet expectations.